drugset / Trial / NCT00797992
Bevacizumab Intravitreal for Myopic Choroidal Neovascularization
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the clinical results of anti-VEGF intra-vitreal injections (IVT) in CNV secondary to pathologic myopia (PM-CNV).
Timeline
- Start
- 2007-01
- Primary completion
- 2008-11
- Completion
- 2008-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 1.25 mg | Intravitreal |